FAPI in Rectal Cancer TNT

NCT06157463 | Recruiting

• 1 other identifier: 202202030A0C601
• Study Type: observational
• Target: 99
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of the trial is to observe the changes of 68Ga FAPI signal before and after total neoadjuvant therapy for rectal cancers, and the correlation between the image parameters, immune checkpoints expression as well as the patient outcome. The trial will recruit patients with biopsy-confirmed rectal cancer aged 18 years old or older, with WHO/ECOG Performance Status 0-1, and eligible for total neoadjuvant therapy at the clinicians' discretion. After signing the informed consent, the participants will undergo a standard staging work-up if not already done, including colonoscopy and cross-sectional images such as CT, MR, and FDG-PET. Kidney function (by serum creatinine) and liver function (by serum alanine aminotransferase) will also be assessed. Only patients with stage II-III rectal cancer will be recruited. If patients meet the inclusion and exclusion criteria, they will undergo the first 68Ga-FAPI PET within 30 days before the beginning of total neoadjuvant therapy. At 22-24 weeks into the TNT, follow-ups for response evaluation will be conducted, including colonoscopy and cross-sectional images such as CT, MR, and FDG-PET. The second 68Ga-FAPI PET will be performed within one month of these exams. Afterward, participants will either undergo surgery or have image follow-ups every 3 months. The participants will be followed up for up to 2 years after the second 68Ga-FAPI PET, and immunochemical staining with CD47, CD73, PD-L1, and FAP on the biopsy or surgical specimens will be performed in one batch to avoid batch-to-batch variation.

Conditions

Rectal Neoplasms Malignant

Outcome Measures

Primary Outcomes (1)

• Change of FAPI SUV

  To compare the FAPI uptake after TNT

  before TNT & 22-24wk into TNT

Secondary Outcomes (1)

• Correlation of FAPI SUV

  2 years after recruitment

Study Arms (1)

observation

Ga-68 FAPI study before and during TNT

Radiation: Ga-68 FAPI

Interventions

Ga-68 FAPI RADIATION

FAPI PET scans will be performed in addition to other staging/restaging work-up

observation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Those patient referred to the tertiary medical center for rectal cancer will be invited to enroll in the study.

You may qualify if:

• Biopsy proven newly detected adenocarcinoma of the rectum
• Clinical stage II-III rectal cancer
• Aged at least 18 years. No upper age limit.
• WHO/ECOG Performance Status 0-1
• Eligible for total neoadjuvant therapy

You may not qualify if:

• Distant metastases found on either CT, MR or FDG-PET
• Prior anticancer therapy for colorectal cancer
• Prior radiotherapy of the pelvic region
• Other concurrent antineoplastic therapy
• Subjects pregnant or breast feeding
• Serious concurrent diseases not compatible with study entry, including active, uncontrolled infections, active, disseminated coagulation disorder, clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia within 6 months before enrolment)
• Neurologic or psychiatric disorders including dementia, uncontrolled seizures, substance abuses, severe depression
• Prior or concurrent malignancy within 3 years prior to enrolment (except non-melanoma skin cancer or cervical carcinoma FIGO stage 0-1)
• Allergic to contrast agents or to the main ingredients or excipients of the experimental radiopharmaceutical 68Ga FAPI, including acetate, ascorbic acid and normal saline
• Those deemed unsuitable for participation in the trial by the investigators.

Sponsors & Collaborators

• Chang Gung Memorial Hospital: lead
• National Science and Technology Council: collaborator

Study Sites (1)

Chang Gung Memorial Hospital

Taoyuan District, 333, Taiwan

RECRUITING

Study Officials

• Shih-hsin Chen, MD PhD

  Chang Gung Medical Foundation

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Shih-hsin Chen, MD PhD

CONTACT

886-3-3281200; yevgenyc@cgmh.org.tw

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2023
• First Posted: December 5, 2023
• Study Start: March 8, 2024
• Primary Completion (Estimated): July 31, 2026
• Study Completion (Estimated): July 31, 2028
• Last Updated: August 7, 2024

Record last verified: 2023-11

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)